AstraZeneca PLC (NASDAQ:AZN) Shares Sold by DE Burlo Group Inc.

DE Burlo Group Inc. cut its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 7.0% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 13,677 shares of the company’s stock after selling 1,029 shares during the period. DE Burlo Group Inc.’s holdings in AstraZeneca were worth $1,066,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. McClarren Financial Advisors Inc. boosted its position in shares of AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares during the period. GHP Investment Advisors Inc. purchased a new stake in shares of AstraZeneca in the second quarter worth about $26,000. Capital Performance Advisors LLP purchased a new stake in shares of AstraZeneca in the third quarter worth about $28,000. Pathway Financial Advisers LLC purchased a new stake in shares of AstraZeneca in the first quarter worth about $29,000. Finally, CANADA LIFE ASSURANCE Co boosted its position in shares of AstraZeneca by 40.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after buying an additional 146 shares during the period. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

AZN opened at $63.20 on Thursday. The firm has a market cap of $195.96 billion, a PE ratio of 30.24, a P/E/G ratio of 1.17 and a beta of 0.47. The business has a fifty day simple moving average of $73.99 and a 200-day simple moving average of $77.95. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter last year, the firm posted $0.87 earnings per share. AstraZeneca’s revenue was up 18.0% compared to the same quarter last year. As a group, equities analysts predict that AstraZeneca PLC will post 4.1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on AZN shares. TD Cowen upped their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Finally, UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.